Circulatory system

Atamyo Therapeutics Announces participation in Conferences and Key Scientific Communications on its LGMD programs

Retrieved on: 
Friday, September 29, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Muscular dystrophy, Natural history, International, Gene, C2, Rentschler, Part, ESGCT, Facial muscles, Neuromuscular disease, Diplomatic mission, Circulatory system, Rigshospitalet, Cell, Public, Oral, European Society of Clinical Microbiology and Infectious Diseases, Therapy, Conference, Pharmaceutical industry, Oyster farming, Nightclub, Rare-earth element, MD

Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).

Key Points: 
  • Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).
  • Stephane Degove, Atamyo CEO, will provide a corporate overview at two forthcoming conferences in October:
    Chardan's 7th Annual Genetic Medicines Conference, held in New York City:
    - Presentation on October 2, at 10:30 AM, in the Embassy room
    Cell & Gene Meeting on the Mesa, held in Carlsbad, CA, on October 10-12, 2023:
    - Presentation on October 10, at 5:15pm, at the Rentschler ATMP Ballroom
    Two upcoming communications at the 28th Annual Congress of the World Muscle Society (3-7 October 2023 in Charleston, SC)
    • Oral Presentation by A. Brureau (Genethon), at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 282 at Ballroom C, on October 4, 2023, 17h15-18h15
    Natural history of limb girdle muscular dystrophy R9: one-year follow-up of a European cohort
    • Oral Presentation by J. Vissing (Copenhagen Neuromuscular Center, Rigshospitale) at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 283 at Ballroom C, on October 4, 2023, 17h15-18h15
    Two communications describing Atamyo’s LGMD programs will be presented at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) that will take place on October 24-27, 2023 in Brussel (Belgium):
    • Oral presentation by Nicolai Preisler, MD, Rigshospitalet, Copenhagen, during the Cardiovascular and muscular diseases session, on Friday October 27, 11h30-13h00 – Le BEL, Tour & Taxis
    Oral presentation on Atamyo’s LGMD-R9 program at the 2023 International Limb-Girdle Muscular Dystrophy Conference (28-29 October 2023, Washington DC)
    • Oral presentation by John Vissing, MD, Rigshospitalet, Copenhagen, during the Clinical Trials Updates (Part 1) Session, on October 29, 11h00am-12h10pm – Constitution Ballroom, Grand Hyatt

Implantable Medical Devices Market to grow by USD 51.1 billion from 2022-2027 | North America to account for 45% of market growth - Technavio

Retrieved on: 
Tuesday, September 26, 2023
LivaNova, Prevalence, Osteoporosis, Abbott Laboratories, Tetraplegia, Segment, National Center for Spinal Disorders, SE, Stryker Corporation, Rheumatoid arthritis, Dental implant, Gout, Hip, Zimmer Biomet, Lupus, Cardinal Health, USD, CDC, Medial knee injuries, Boston Scientific, Circulatory system, Growth, Assurant, Orthopedic surgery, Trauma, Clifton Springs Hospital & Clinic, Arthritis, Hospital, NuVasive, Research, Arthropathy, Knee, Laboratory, AbbVie, Ophthalmic, ROW, Korea Disease Control and Prevention Agency, Fibromyalgia, Medtronic, Medical device, Retail, Application, Geography

NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.
  • Hence, such factors drive the growth of the implantable medical devices market during the forecast period.
  • Detailed information on factors that will drive the growth of the implantable medical devices market between 2022 and 2027.
  • Growth of the implantable medical devices market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of implantable medical devices market vendors.

Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023

Retrieved on: 
Friday, September 8, 2023
Cardiovascular and Interventional Radiological Society of Europe, Miniature, ZEUS robotic surgical system, Clinical trial, Coronavirus Scientific Advisory Board, CIRSE, Doctor of Philosophy, Aix-Marseille University, MDR, Professor, Circulatory system, FIH, FDA, Microbotics

BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.

Key Points: 
  • BRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023.
  • The abstract is to be presented by Professor of Interventional Radiology Vincent Vidal, M.D.
  • PhD, from the Aix-Marseille University and a Scientific Advisory Board Member of Microbot.
  • The team expressed their positive experiences and satisfaction from using the Company’s Robotic Surgery System.

IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress

Retrieved on: 
Friday, September 8, 2023
ENT, Endometriosis, CE, Abstract, IR, Plantar fibromatosis, Travel, Ablation, Cryoablation, Q&A, Neoplasm, Woman, Breast, CIRSE, Doctor of Philosophy, Lung, Congress, CHU, Traction, Freezing, Circulatory system, Cardiovascular and Interventional Radiological Society of Europe, Kidney, Liver, Malignancy, LN2, Medical imaging, Management, MD

IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.

Key Points: 
  • IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.
  • IceCure will be participating in the Tumor Ablation Hands-On Device Training with the ProSense cryoablation system.
  • This is a great opportunity for attendees to gain hands-on knowledge of IceCure's cryoablation device and to see the system's advantages.
  • Thanks to this grant, ten aspiring women interventional radiologists' abstracts were accepted and will receive sponsored congress registration, travel, and accommodation.

NeurAxis Highlights Strength of its Board of Directors

Retrieved on: 
Thursday, August 24, 2023
TMD, Sharecare, Senior, Head, GPO, United States Army Reserve Command, NYSE, Executive, General Electric, Capital market, Private practice, Neuraxis, Cath, Fort Benjamin Harrison, Circulatory system, Ernst, Create, Anesthesiology, Ernst & Young, LLP, International, Health, Chronic pain, Finance, USAR, Engineering, Federal Signal Corporation, Electrophysiology, International Auditing and Assurance Standards Board, Audit, Army Reserve, BCBS, Blue Cross Blue Shield Association, American Academy, Neck, School, Mergers and acquisitions, Follett Corporation, St. Jude Medical, Management, Anthem

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.

Key Points: 
  • CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.
  • “We are fortunate to have a board with a depth of experience in relevant areas to NeurAxis, including medical device commercialization, commercial insurance, and finance.
  • “We are excited to have this strength at the board level as we continue to develop and drive adoption of our IB Stim Therapy™,” concluded Mr. Carrico.
  • The Company’s Board of Directors includes:
    Ms. Keyser has more than 20 years of experience in executive roles in population health.

Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Bristol Myers Squibb, Apixaban, Senior, ESC Congress, Atrial fibrillation, NVAF, European Society of Cardiology, Research, SOC, BMY, Congress, MD, Standard of care, Patient, Risk, Circulatory system, Rivaroxaban, ESC, NYSE, LTE, Safety, Ventricular fibrillation, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023.
  • The Bristol Myers Squibb-Pfizer Alliance will also share an observational retrospective real-world study on the clinical impact of switching or continuation of Eliquis® (apixaban) or rivaroxaban among patients with non-valvular atrial fibrillation (NVAF).
  • “This year’s ESC Congress provides the opportunity to present new data spanning our cardiovascular portfolio, reinforcing our ambition of bringing innovative and life-changing medicines to patients living with cardiovascular diseases,” said Roland Chen, MD, Senior Vice President and Head of Cardiovascular & Neuroscience Development, Global Drug Development.
  • Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at ESC Congress 2023 include:

Expanse Medical Welcomes Shlomi Nachman to Board of Directors

Retrieved on: 
Monday, August 21, 2023
Knowledge, Intact Insurance Specialty Solutions, Partnership, Circulatory system, Pharmaceutical industry, Management

PLEASANTON, Calif., Aug. 21, 2023 /PRNewswire/ -- Expanse Medical, the innovative medical device incubator founded by Eitan Konstantino with focus on global innovations, proudly announces the addition of Shlomi Nachman to its Board of Directors and the Board of its spinoff, Expanse ICE.

Key Points: 
  • PLEASANTON, Calif., Aug. 21, 2023 /PRNewswire/ -- Expanse Medical, the innovative medical device incubator founded by Eitan Konstantino with focus on global innovations, proudly announces the addition of Shlomi Nachman to its Board of Directors and the Board of its spinoff, Expanse ICE.
  • As a hub for worldwide medical advancements, Expanse Medical has unwavering commitment to introducing next-generation medical solutions.
  • Eitan Konstantino, founder of Expanse Medical, conveyed his excitement, stating, "Our vision has always been to identify and nurture global medical innovations.
  • Expanse Medical looks forward to the wealth of knowledge, expertise, and leadership Mr. Nachman will bring to the board.

Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company

Retrieved on: 
Monday, August 14, 2023
LeMaitre Vascular, CDC, Lemaître, Osteon, Patient, Circulatory system, Growth, FDA, Orthopedic surgery, Safety, Medical device, Video game

SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • “Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company continues to move forward," said Dr. Randy Mills, President and Chief Executive Officer of Aziyo Biologics.
  • Net sales for the second quarter of 2023 were $10.3 million, compared to $12.6 million in the second quarter of 2022.
  • Net loss per share in the second quarter of 2023 was $0.65 per share, as compared to a loss of $0.69 per share in the second quarter of 2022.
  • Aziyo will host a conference call today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its second quarter 2023 financial results and performance.

In Celebration of "Orgasm Day" The Cellular Medicine Association Offers a Free Course, The Female Orgasm System

Retrieved on: 
Thursday, July 27, 2023
Food, CMA, Life, Female reproductive system, Education, Anxiety, Physician, Respiratory disease, Circulatory System (band), Circulatory system, Orgasm, Respiratory system of insects, Respiratory system, Woman, Medicine, DSM-IV codes, Systems analysis, Platelet-rich plasma, Trachea, Blood, Reproductive system, Testosterone and the cardiovascular system, CQD, Anorgasmia, Child, Anemia, Engineering, Aesthetics, Pleasure, Periodic breathing, Diagnosis, Erectile dysfunction, Research, Book, Music, Female, Urinary incontinence, Nursing, Publishing, Medical device, MD

Music and food are sometimes called "orgasmic" because orgasm is considered to be the ultimate pleasure; but orgasm is not just about pleasure.

Key Points: 
  • Music and food are sometimes called "orgasmic" because orgasm is considered to be the ultimate pleasure; but orgasm is not just about pleasure.
  • Similarly, the Reproductive System and the Orgasm System share components but are not the same."
  • Dr. Runels, the inventor of the O-Shot® procedure , author of multiple research papers and books, and first to use the terminology "Female Orgasm System," is offering an online seven-week course teaching the Female Orgasm System in hopes of narrowing the orgasm gap.
  • The course is sponsored by the Cellular Medicine Association (CMA) .

AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Health Technology, Health, Oncology, Ohio State University, Medtronic, University, Quality of life, Customer service, Business administration, Patient, Circulatory system, Communication, Mid-America Regional Council, CFO, Growth, Drug, Management, Finance

While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions.

Key Points: 
  • While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions.
  • Burgess’ impressive career has been marked by her ability to shape and execute transformative strategies that drive growth and remarkable profitability,” said Jim Clemmer, AngioDynamics President and CEO.
  • Ms. Burgess is a member of the Board of Directors for Stepan Company.
  • With Ms. Burgess’ appointment, AngioDynamics’ total number of directors will increase to nine members.